Search
delafloxacin; delafloxacin meglumine (Baxdela)
Indications:
- skin infections, including MRSA [1]
Dosage:
- 300 mg IV q12hr for 5-14 days, OR
- 300 mg IV q12hr, then switch t450-mg PO q12hr for 5-14 days, OR
- 450 mg PO q12hr for 5-14 days
Mechanism of action:
- fluoroquinolone antibiotic
- inhibits both bacterial topoisomerase IV & DNA gyrase (topoisomerase II)
Interactions
drug adverse effects of fluoroquinolones
General
fluoroquinolone
Database Correlations
PUBCHEM correlations
References
- Lowes R
FDA Approves Delafloxacin (Baxdela) for Skin Infections
Medscape - Jun 19, 2017.
http://www.medscape.com/viewarticle/881827
- Windle ML.
FDA New Drug and Biologic Approvals -- 2017 Year-in-Review
Medscape - Jan 11, 2018.
https://reference.medscape.com/viewarticle/890871
- U.S. Food and Drug Administration.
Novel Drug Approvals for 2017.
https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DrugInnovation/ucm537040.htm
- Baxdela (delafloxacin) prescribing information.
Melinta Therapeutics, Inc. Lincolnshire, IL. June 2017.
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208610s000,208611s000lbl.pdf